A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
2022 ◽
Vol Publish Ahead of Print
◽
2019 ◽
Vol 39
(10)
◽
pp. 931-938
◽